Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Bevacizumab +/- Rucaparib in Relapsed Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT02873962Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2016
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and rucaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Objective Response Rate at 18 months and Tolerability at 100 days. Started Nov 2016; status: active, not recruiting.
02
Drugs
nivolumabrucaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02873962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873962.